BI_1467335



NAME OF DRUG : BI_1467335

ALSO KNOWN AS : BI_1467335 or PXS-4728A

LABORATORY : Boehringer_Ingelheim

STATUS AND ADVANCEMENT

Type of drug : VAP-1/AOC3 protein inhibitor

Clinical trials advancement : Recruiting Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated time to market : 97 months.

LABORATORY ABSTRACT ON THE DRUG

The compound is an oral inhibitor of amine oxidase, copper containing 3 (AOC3)1, and works by blocking leucocyte adhesion and tissue infiltration in inflammatory processes underlying NASH.

RECENT NEWS ON BI_1467335

2014-08-24 : Boehringer Ingelheim and pharmaceutical company Pharmaxis announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A)

SOME PUBLICATIONS RELATED WITH BI_1467335

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH BI_1467335


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE